MFS
CGEM icon

Mirabella Financial Services’s Cullinan Oncology CGEM Stock Holding History

Mirabella Financial Services’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29,686
Closed -$670K – 429
2021
Q3 		$670K Buy
+29,686
New +$794K 0.09% 207

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mirabella Financial Services's CGEM Position: Q4 2021 in Review

Mirabella Financial Services sold out of Cullinan Oncology (CGEM) in Q4 2021, closing a stake of 29,686 shares — an estimated $670K sold.

Mirabella Financial Services first reported a position in CGEM in Q3 2021 and held it in 1 quarter. The position peaked at $670K in Q3 2021. 75 funds tracked by Wall St. Rank hold CGEM as of Q4 2021.

  • Mirabella Financial Services reported no remaining Cullinan Oncology position as of Q4 2021 after selling out during the quarter.
  • Mirabella Financial Services sold 29,686 Cullinan Oncology shares in Q4 2021, an estimated $670K.
  • Mirabella Financial Services first reported a position in Cullinan Oncology in Q3 2021 and held it in 1 quarter.
  • Mirabella Financial Services's Cullinan Oncology position peaked at $670K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2021.

Based on Mirabella Financial Services's 13F filing for Q4 2021, filed 14 Feb 2022.